Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 2/20 | 0.42 |
| ▸ | CLK3 | P49761 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1593369 | 0.89 | LRRK2 (0.52) | CNR2CNR1KDRCHEK1PARP1 | |
| SCHEMBL1593689 | 0.77 | AURKA (0.41) | CLK2CLK3DYRK1APARP1 | |
| SCHEMBL14235967 | 0.76 | BRAF (0.45) | CLK2CLK3DYRK1A | |
| SCHEMBL3375853 | 0.75 | DRD4 (0.53) | CNR2CNR1KDRCLK2CLK3 | |
| SCHEMBL1592857 | 0.73 | ALDH1A1 (0.46) | CLK2DYRK1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8034828 | 0.73 | BRAF (0.46) | KDRCLK2CLK3DYRK1A | |
| SCHEMBL1592922 | 0.73 | NUDT1 (0.47) | ADORA2AADORA1 | |
| SCHEMBL1593552 | 0.73 | ADORA2A (0.46) | ADORA2A | |
| SCHEMBL16344704 | 0.72 | GSK3B (0.57) | CNR2CNR1CHEK1 | |
| SCHEMBL13572689 | 0.71 | CHEK1 (0.61) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394795-B2 | Pyrazole [3, 4-B] pyridine Raf inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2265610-B1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | BRAF, RAF1, ARAF | CNR2 3546/4885CNR1 3221/4885KDM5B 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.